Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Unknown 2Terminated 2Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

NCT03603964 2024-08-27

Guadecitabine Extension Study

Astex Pharmaceuticals, Inc.

Phase 2 Terminated
35 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡